NEW YORK, July 22 - Ambion, of Austin, Texas, has exclusively licensed short interfering RNA technology described in a patent application from the City of Hope National Medical Center and Beckman Research Institute, the company said today.
The application stems from an invention by John Rossi, chair of the division of Molecular Biology at City of Hope Comprehensive Cancer Center. It covers technologies for expressing siRNA from PCR products, the company said. This technology is designed for quick preparation of siRNA expression cassettes without cloning or sequencing.
The company, which sells a variety of siRNA-related products to the research market, did not disclose the financial terms of the licensing deal.